0.320
0.000
(0.00%)
May 24 - Close
TSE
data delayed by 15 mins -
Disclaimer
Currency in CAD
| Range | 0.32 - 0.32 |
| 52 week | 0.24 - 1.15 |
| Open | 0.32 |
| Vol / Avg. | 1,000.00/252,843.00 |
| Mkt cap | 15.18M |
| P/E | - |
| Div/yield | - |
| EPS | -0.73 |
| Shares | 47.43M |
| Beta | 1.60 |
| Inst. own | - |
Events
May 22, 2013
Bellus Health Inc. at Bloom Burton & Co. Healthcare Investor Conference
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -49.81% | -573.11% |
| Operating margin | 1406.67% | 197.26% |
| EBITD margin | - | -157.40% |
| Return on average assets | -3.94% | -66.83% |
| Return on average equity | -13.23% | - |
| Employees | 8 | - |
| Carbon Disclosure Rating | - | - |
Address
275 Armand-Frappier Blvd.
LAVAL, QC H7V 4A7
Canada
+1-450-6804500 (Phone)
+1-450-6804501 (Fax)
LAVAL, QC H7V 4A7
Canada
+1-450-6804500 (Phone)
+1-450-6804501 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
BELLUS Health Inc. (BELLUS Health) is a development-focused healthcare company. The Company is focusing on products, which provides health solutions and address medical needs. The Company�s product portfolio includes two pharmaceutical drug candidates and one commercial stage nutraceutical product, which include KIACTA, BLU8499 and VIVIMIND. BELLUS Health� primary focus is on advancing KIACTA, a treatment for AA amyloidosis through a pivotal Phase III Confirmatory Study. BELLUS Health is also developing BLU8499 a prodrug of tramiprosate. VIVIMIND is a natural health product designed to protect memory function. In September 2012, BELLUS Health entered into a license and distribution agreement with Lifenergy Biotech Corp. (Lifenergy), pursuant to which the Company granted Lifenergy distribution rights for VIVIMIND in Taiwan.